Mastering Psoriasis Management Guidelines for SCE Dermatology Success

Psoriasis is a chronic, immune-mediated inflammatory skin condition that frequently appears in dermatology examinations. For candidates preparing for the SCE (Specialist Certification Exam) in Dermatology, a thorough understanding of current management guidelines is essential. This comprehensive guide covers the key aspects of psoriasis diagnosis, classification, and treatment according to latest UK guidelines.

Understanding Psoriasis: Clinical Presentation

Psoriasis affects approximately 2-3% of the UK population and presents in several clinical variants:

• Plaque Psoriasis: Most common form (80-90% of cases), characterized by well-demarcated, erythematous plaques with silvery scale

• Guttate Psoriasis: Small, drop-shaped lesions often following streptococcal infection

• Inverse Psoriasis: Smooth, shiny lesions in flexural areas

• Pustular Psoriasis: Sterile pustules, which can be localized or generalized

• Erythrodermic Psoriasis: Widespread redness covering >90% body surface area

Assessment and Severity Scoring

Before initiating treatment, proper assessment is crucial. The Psoriasis Area and Severity Index (PASI) is the gold standard for measuring psoriasis severity and monitoring treatment response. A PASI score >10 or involvement of >10% body surface area generally indicates moderate-to-severe disease requiring systemic therapy.

The Dermatology Life Quality Index (DLQI) is also essential for assessing the psychosocial impact and determining treatment eligibility.

First-Line Management: Topical Therapies

Emollients and Moisturizers

Emollients form the foundation of psoriasis management:

• Daily application of emollients (e.g., unguentum, aqueous cream, epaderm)

• Apply generously and frequently, especially after bathing

• Can be used alone for mild disease or as adjunct to other treatments

Topical Corticosteroids

Topical steroids remain cornerstone therapy:

• Mild potency (hydrocortisone 1%): For facial and intertriginous psoriasis

• Moderate potency (betamethasone valerate 0.025%): For body lesions

• Potent (betamethasone dipropionate 0.05%): For thick plaques on extensor surfaces

• Very potent (clobetasol propionate): For stubborn plaques, limited to 2-week courses

Key Principle: Use weakest effective potency for shortest duration to minimize side effects.

Vitamin D Analogues

Calcipotriol (calcipotriene) is first-line for plaque psoriasis:

• Apply twice daily to affected areas

• Often combined with topical steroids (calcipotriol/betamethasone gel/ointment)

• Maximum 100g per week to avoid hypercalcaemia

Calcineurin Inhibitors

Tacrolimus and pimecrolimus for sensitive areas:

• Particularly useful for facial, intertriginous, and genital psoriasis

• No risk of skin atrophy

• May cause initial burning sensation

Phototherapy

For moderate-to-severe disease inadequately controlled with topical therapy:

Narrowband UVB

• First-line phototherapy option

• 2-3 sessions per week

• 70-80% response rate

• Cumulative exposure limits apply to minimize skin cancer risk

PUVA (Psoralen + UVA)

• Oral or bath psoralen followed by UVA

• Effective but requires careful monitoring

• Higher long-term skin cancer risk than UVB

Systemic Therapies

Conventional Systemic Agents

For moderate-to-severe psoriasis:

Methotrexate:

• First-line systemic agent

• Starting dose: 2.5-5mg weekly, titrating to 15-25mg weekly

• Requires baseline and ongoing monitoring (LFTs, FBC, renal function)

• Folic acid 5mg weekly (taken 24-48 hours after methotrexate)

• Contraindicated in pregnancy, liver disease, significant renal impairment

Ciclosporin:

• Rapid onset of action

• Dose: 2.5-5mg/kg/day in divided doses

• Short-term use only (max 1 year)

• Monitor blood pressure, renal function

• Drug interactions common (check with BNF)

Acitretin:

• Only oral retinoid for psoriasis

• Dose: 25-50mg daily

• Teratogenic - strict contraception required

• Side effects: cheilitis, dry eyes, hyperlipidaemia

Biologic Therapies

For severe disease failing conventional systemic therapy:

TNF-alpha inhibitors:

• Adalimumab: 40mg subcutaneous every 2 weeks

• Infliximab: Loading dose then every 8 weeks

• Etanercept: 50mg twice weekly for 12 weeks, then 50mg weekly

IL-17 inhibitors:

• Secukinumab: 300mg at weeks 0, 1, 2, 3, 4, then monthly

• Ixekizumab: 160mg at week 0, then 80mg every 2 weeks

IL-23 inhibitors:

• Ustekinumab: Weight-based dosing at weeks 0, 4, then every 12 weeks

• Guselkumab: 100mg at weeks 0, 4, then every 8 weeks

IL-12/23 inhibitor:

• Ustekinumab (as above)

Small Molecule Inhibitors

Apremilast:

• PDE4 inhibitor

• Oral agent for moderate-to-severe psoriasis

• Starting dose: 10mg daily, titrating to 30mg twice daily by day 6

• Better side effect profile than traditional systemics

• Requires monitoring for depression

Special Considerations

Psoriatic Arthritis

• 30% of psoriasis patients develop psoriatic arthritis

• Early referral to rheumatology essential

• Treatment may require disease-modifying antirheumatic drugs (DMARDs)

• TNF inhibitors particularly effective

Pregnancy and Lactation

• Emollients and topical steroids (hydrocortisone, betamethasone) are safe

• Avoid methotrexate, acitretin, and biologics if possible

• Consult specialist for individualised management

Vaccination

• Live vaccines contraindicated on biologic therapies

• Inactivated vaccines safe but may have reduced response

• Annual influenza and pneumococcal vaccination recommended

SCE Exam Tips

1. Know the step-up approach: Topicals → Phototherapy → Systemic → Biologics

2. Remember PASI scoring: Crucial for defining moderate-to-severe disease

3. Drug monitoring schedules: Be familiar with baseline and follow-up investigations for each systemic agent

4. Contraindications: Know key contraindications for each treatment

5. Combination therapy: Often more effective - know common combinations (e.g., topical vitamin D + steroid)

6. Quality of life: Always consider DLQI in treatment decisions

7. Comorbidities: Screen for cardiovascular disease, depression, and psoriatic arthritis

Conclusion

Psoriasis management has evolved significantly with the advent of biologic therapies. For SCE Dermatology success, candidates must understand the stepwise approach to treatment, from emollients and topicals through to systemic therapies and biologics. Key examination points include appropriate severity assessment, selection of first-line therapies, monitoring requirements, and recognition of when to escalate treatment.

Remember: The goal is to achieve clear or almost clear skin (PASI 90) while minimizing treatment side effects and maintaining quality of life.

This guide is based on current NICE guidelines and standard UK dermatology practice. Always refer to the latest BNF and local guidelines for prescribing decisions.